[HTML] sciencedirect.com

[HTML][HTML] Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label …

Y Cheng, TS Mok, X Zhou, S Lu, Q Zhou, J Zhou, Y Du… - Lung Cancer, 2021 - Elsevier
Objectives To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …
被引用次数：24 相关文章

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 …

Y Cheng, TS Mok, X Zhou, S Lu… - Lung cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 …

Y Cheng, TS Mok, X Zhou, S Lu, Q Zhou… - Lung Cancer …, 2021 - europepmc.org
Objectives To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …
[HTML] lungcancerjournal.info

[HTML][HTML] Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label …

Y Cheng, TS Mok, X Zhou, S Lu, Q Zhou… - Lung …, 2021 - lungcancerjournal.info
Objectives To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy
for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing …